Skip to content

    GEMAROMA

    GEMAROMA
    Chemicals·27 Jan 2026
    Management Summary

    GEM Aromatics reported a mixed Q3 FY26, with consolidated revenue at INR 78.9 crores and a net loss of INR 5 crores, primarily due to higher depreciation from the newly commissioned Dahej facility. However, gross and EBITDA margins saw significant quarter-on-quarter improvement, reaching 23% and 8.9% respectively. The company remains optimistic about its long-term growth, targeting INR 1,050-1,100 crores revenue by FY28 with 16-18% EBITDA margins, driven by the Dahej facility's ramp-up and product diversification despite ongoing external headwinds.

    Highlights

    5
    • Consolidated Gross Profit margin improved significantly to 23% in Q3 FY26, up from 14% in Q2 FY26.

    • Consolidated EBITDA margin improved to 8.9% in Q3 FY26, up from 3% in Q2 FY26, supported by gradual recovery in mint prices and better customer alignment.

    • The Greenfield Dahej facility successfully commissioned cooling agents (WS23, WS03) and clove/eugenol verticals on December 11, 2025, and completed first-stage audits for various certifications.

    • The company is targeting substantial revenue growth to INR 1,050-1,100 crores by FY28 with healthy EBITDA margins of 16-18%.

    • New products at Krystal (Dahej) are largely tariff-exempt for the US market, and the company is pursuing a dual US+1 strategy to mitigate tariff risks.

    Concerns

    4
    • Consolidated net loss for Q3 FY26 was INR 5 crores.

    • Profitability was impacted by higher depreciation of INR 8.7 crores, a non-cash charge, following the capitalization of approximately INR 250 crores capex at the Dahej facility.

    • Revenues were impacted by external headwinds, including tariff-related uncertainty and GST-related changes, influencing customer procurement behavior.

    • Contribution from the newly commissioned Dahej facility was limited in Q3 FY26, as operations were restricted to only approximately 20 days.

    Key financials

    Single quarter

    06 metrics
    1. 01Consolidated Revenue₹78.9 Cr
    2. 02Consolidated Gross Profit₹18.2 Cr
    3. 03Consolidated Gross Margin23%+64.3%QoQ
    4. 04Consolidated EBITDA₹7 Cr
    5. 05Consolidated EBITDA Margin8.9%+2.0%QoQ

    Capital allocation

    1
    high confidence
    CategoryHeadline
    Capex

    ₹270 crores

    Guidance & targets

    9
    CategoryTargetPriority
    Revenue
    Revenue target
    INR 1,050-1,100 crores
    High
    Revenue
    Dahej facility peak revenue
    INR 750-800 crores
    High
    Profitability
    EBITDA Margin target
    16-18%
    High
    Profitability
    Krystal (Dahej) cash breakeven
    Cash breakeven
    High
    Capacity Utilization
    Dahej facility utilization
    50-60%
    High
    Product Development
    Catalyst preparation for Phenol Derivatives
    Completed
    High
    Product Development
    Trial production of Anisole, MEHQ, Guaiacol
    Planned
    High
    Revenue Contribution
    Krystal (Dahej) revenue contribution
    INR 650-700 crores
    Medium
    Revenue Contribution
    GEM (Budaun/Silvassa) revenue contribution
    INR 400 crores
    Medium

    Dahej facility ramp-up and utilization

    Q4 FY26 onwards, 50-60% by Q1 FY28
    CurrentLimited contribution (20 days) in Q3 FY26
    TargetMeaningful contribution, progress towards 50-60% utilization

    Why it matters

    Crucial for achieving long-term revenue and margin targets, as it represents a 3x capacity expansion.

    We expect a more meaningful contribution from Q4 FY '26 onwards as new products are launched and capacity ramp-up begins... we expect like 50%-60% by next year, by next year end.

    How to verify

    key_financials.metrics[label='Consolidated Revenue']

    Risks & concerns

    6
    RiskSeverity

    External headwinds impacting revenue

    Revenues impacted by tariff-related uncertainty and GST-related changes, influencing customer procurement behavior and demand.Management acknowledged

    medium

    Higher depreciation impacting profitability

    Profitability impacted by higher depreciation of INR 8.7 crores, a non-cash charge, following capitalization of Dahej capex.Management acknowledged

    low

    Limited initial contribution from new Dahej facility

    Dahej facility's contribution was limited in Q3 FY26 due to operations being restricted to approximately 20 days post-commissioning.Management acknowledged

    low

    Competition in MEHQ market

    Analyst noted new entrants like Vinati and existing players like Clean Science in MEHQ, but management expressed confidence in its technology and downstream derivatives.Analyst downplayed

    medium

    Impact of unorganized sector on GST

    The GST issue is primarily with the unorganized and fragmented smaller suppliers/customers where price is the only consideration, and management feels it is here to stay for some time.Management acknowledged

    low

    Geopolitical factors affecting global scenarios

    Headwinds from changing global scenarios due to current geopolitics make the long due diligence process for customer approvals challenging.Management acknowledged

    medium

    Q&A highlights

    8

    “It is actually improving realizations compared to Q2. It is also coming in from our US subsidiary, which is GEM LLC, where realization and demand to the extent that some inventory has been exhausted with a few customers, they have started ordering, although at a slower pace. So, that also helps realizations come up and then the margins.”

    Analyst questioned the sharp margin rise, and management attributed it to improved realizations and contribution from the US subsidiary, indicating a demand recovery.

    asked by Kamlesh Bagmar

    2 min read5 chapters

    Detailed Narrative

    01

    Q3 FY26 Financial Performance and Margin Improvement

    In Q3 FY26, Gem Aromatics reported consolidated revenue from operations of INR 78.9 crores. Despite a net loss of INR 5 crores, primarily due to higher depreciation, the company demonstrated significant margin improvement. Consolidated Gross Profit margin expanded from 14% in Q2 FY26 to 23% in Q3 FY26, while consolidated EBITDA margin improved from 3% to 8.9% quarter-on-quarter. This margin expansion was attributed to improved realizations, a gradual recovery in mint prices, and better customer alignment.

    02

    Dahej Greenfield Facility Commissioning and Capacity Expansion

    The company made significant progress at its Greenfield Dahej facility, which is a key pillar for long-term growth. The facility commissioned cooling agents (WS23 and WS03) and clove/eugenol verticals on December 11, 2025. With a total capital expenditure of approximately INR 270 crores (INR 250 crores already incurred), the Dahej plant will increase the company's total capacity to 16,000 MTPA, representing an effective 3x expansion. The plant has also successfully completed first-stage audits for various global compliance certifications.

    03

    Product Diversification and Phenol Derivatives Strategy

    Gem Aromatics is expanding beyond its mint-centric business towards a diversified specialty ingredients platform. The Dahej facility will enable manufacturing capabilities across Clove and Clove Derivatives, Citral Derivatives, Phenol Derivatives, and Cooling Agents. For Phenol Derivatives, catalyst preparation is expected to be completed by Q4 FY26, with trial production of Anisole, MEHQ, and Guaiacol planned for Q1 FY27. The company intends to manufacture Anisole in-house to gain cost advantages for downstream products, focusing on margin-accretive derivatives for the flavor and fragrance industry.

    04

    Market Headwinds and Mitigation Strategies

    Revenues in Q3 FY26 were impacted by external headwinds🌐, including tariff-related uncertainty and GST-related changes, which influenced customer procurement behavior. The company noted that approximately 60% of its FY25 exports to the US market were under tariffs, causing pain. To mitigate these risks, Gem Aromatics is pursuing a 'dual US plus one' strategy, focusing on tariff-exempt products for the US and expanding exposure to the European markets, anticipating benefits from the India-EU trade deal.

    05

    Long-term Growth Outlook and Targets

    The company is confident in its growth trajectory, targeting revenue of INR 1,050-1,100 crores by FY28, with EBITDA margins in the range of 16-18%. The Dahej facility is expected to reach 50-60% utilization by Q1 FY28 and generate INR 750-800 crores in revenue by FY29, based on a 3x asset turnover. Krystal (Dahej) is projected to achieve cash breakeven by FY27 at approximately 45% capacity utilization, contributing INR 650-700 crores to the FY28 revenue target, with the remaining INR 400 crores from existing GEM facilities.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.